- FDA approves easy-to-use injectable methotrexate for RA, psoriasis, juvenile arthritis
- Antares announces availability of injectable methotrexate product for arthritis, psoriasis
- Campaign to educate patients about psoriatic arthritis
- FDA approves UCB's Cimzia for psoriatic arthritis
- Appropriations bill to boost funding for Lupus Research Institute's education program
PORTLAND, Ore. — The National Psoriasis Foundation and the Arthritis Foundation are presenting the country's first program specifically devoted to psoriatic arthritis this week, the two organizations said Monday.
The groups will sponsor the event, Be Joint Smart, at Queens College in New York, on Saturday.
According to the two organizations, 30% of people with psoriasis, which is the most common autoimmune disease in the country, actually have psoriatic arthritis, an inflammatory disease that causes pain, swelling and stiffness of the joints and tendons. Up to 2 million Americans are currently diagnosed with the disease, and the National Psoriasis Foundation says that nearly one-quarter of people with psoriasis may have undiagnosed psoriatic arthritis.